LONG-TERM FOLLOW-UP FROM THE PHASE 1/2 MAJESTEC-1 TRIAL OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: SUBGROUP ANALYSIS BY LINES OF THERAPIES by LJ Costa, NWCJV Donk, L Rosinol, R Popat, Be semer, J Martinez-Lopez, D Trancucci, T Stephenson, K Chastain, N Bahlis

Get full text

TECLISTAMAB IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RRMM): MAJESTEC-1 SUBGROUP ANALYSIS BY LINES OF THERAPIES by NWCJV Donk, R Popat, L Rosiol, B Besemer, JM Lopez, D Trancucci, R Verona, T Stephenson, K Chastain, N Bahlis

Get full text

PB2020: MAJESTEC-3: RANDOMIZED, PHASE 3 STUDY OF TECLISTAMAB PLUS DARATUMUMAB VERSUS DPD OR DVD IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA by M. V. Mateos, N. Bahlis, L. Costa, A. Perrot, L. Pei, M. Rubin, K. Lantz, W. Sun, M. Jaffe, R. Kobos, A. Nooka

Get full text

P897: UPDATED RESULTS FROM THE ONGOING PHASE 1 STUDY OF ELRANATAMAB, A BCMA TARGETED T-CELL REDIRECTING IMMUNOTHERAPY, FOR PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA by A. Dalovisio, N. Bahlis, N. Raje, C. Costello, B. Dholaria, M. Solh, M. Levy, M. Tomasson, H. Dube, M. Damore, S. Jiang, C. Basu, A. Skoura, E. Chan, S. Trudel, A. Jakubowiak, M. Chu, C. Gasparetto, M. Sebag, A. Lesokhin

Get full text

S184: EVALUATING TECLISTAMAB IN PATIENTS WITH RELAPSED/ REFRACTORY MULTIPLE MYELOMA FOLLOWING EXPOSURE TO OTHER B-CELL MATURATION ANTIGEN (BCMA)-TARGETED AGENTS by C. Touzeau, A. Krishnan, P. Moreau, A. Perrot, S. Z. Usmani, S. Manier, M. Cavo, C. Martinez-Chamorro, A. Nooka, T. Martin, L. Karlin, X. Leleu, N. Bahlis, B. Besemer, L. Pei, R. Verona, S. Girgis, C. Uhlar, R. Kobos, A. Garfall

Get full text

P936: TIME TO RESPONSE, DURATION OF RESPONSE, AND PATIENT-REPORTED OUTCOMES WITH DARATUMUMAB PLUS RD VS RD ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NDMM: SUBGROUP ANALYSIS OF T... by T. Facon, S. K. Kumar, T. Plesner, P. Moreau, N. Bahlis, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. P. Venner, K. Weisel, J. R. Mace, N. Raje, M. Tiab, M. Macro, L. Frenzel, X. Leleu, H. Pei, F. Borgsten, S. Z. Usmani

Get full text

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATION ANTIGEN–DIRECTED THERAPIES: A POOLED ANALYSIS FROM MAGNETISM... by A Nooka, A Lesokhin, M Mohty, R Niesvizky, C Maisel, B Arnulf, S Larson, A Varshavsky-Yanovsky, X Leleu, L Karlin, D Vesole, N Bahlis, CF Larrea, N Raje, E Leip, U Conte, M Elmeliegy, A Viqueira, V Blunk, S Manier

Get full text

P940: SAFETY AND CLINICAL ACTIVITY OF BELANTAMAB MAFODOTIN WITH PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): DREAMM-4 STUDY by A. Suvannasankha, N. Bahlis, S. Trudel, K. Weisel, C. Koenecke, A. Oriol, P. M. Voorhees, A. A. Alonso, N. S. Callander, M. V. Mateos Manteca, N. Reddy, S. Hakim, N. Patel, D. Williams, R. C. Jewell, X. Zhou, I. Gupta, A. K. Nooka

Get full text

ELRANATAMAB, A B-CELL MATURATION ANTIGEN-CD3 BISPECIFIC ANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM THE MA... by M Mohty, M Tomasson, B Arnulf, N Bahlis, M Prince, R Niesvizky, P Rodrgue-Otero, J Martine-Lopez, G Koehne, Y Jethava, A Gabayan, D Stevens, A Nooka, N Raje, S Iida, E Leip, U Conte, A Czibere, A Viqueira, V Blunk, A Lesokhin

Get full text

S170: DYNAMIC INTERPLAY BETWEEN TUMOR AND MICRO-ENVIRONMENT DURING MYELOMA DISEASE PROGRESSION by M. C. Köse, I. Bergiers, M. Malfait, B. Heidrich, D. De Maeyer, N. Fourneau, B. Verbist, J. Van Houdt, G. Vanhoof, R. Verona, M. Delforge, J. Depaus, N. Meuleman, J. Van Droogenbroeck, P. Vlummens, C. J. Heuck, N. Bahlis, J. Caers, T. Casneuf

Get full text

P16 HEALTH-RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP... by T. Facon, T. Plesner, S. Usmani, S. Kumar, N. Bahlis, C. Hulin, R. Orlowski, H. Nahi, P. Mollee, K. Ramasamy, M. Roussel, A. Jaccard, M. Delforge, L. Karlin, B. Arnulf, A. Chari, H. Pei, N. Gupta, S. Kaila, K. Matt, K. Gries, R. Carson, F. Borgsten, K. Weisel, A. Perrot

Get full text

P898: COMPARISON OF TECLISTAMAB WITH BELANTAMAB MAFODOTIN IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA USING MATCHING-ADJUSTED INDIRECT TREATMENT COMP... by M. Delforge, S. Z. Usmani, N. W. van de Donk, A. L. Garfall, P. Moreau, A. Oriol, A. K. Nooka, L. Rosinol, N. Bahlis, P. Rodriguez-Otero, T. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, A. Krishnan

Get full text

P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D-RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT-INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA... by K. Weisel, S. Kumar, P. Moreau, N. Bahlis, T. Facon, T. Plesner, R. Orlowski, S. Basu, H. Nahi, C. Hulin, H. Quach, H. Goldschmidt, M. O’Dwyer, A. Perrot, C. Venner, N. Raje, M. Tiab1, M. Macro, L. Frenzel, X. Leleu, H. Pei, M Krevvata, R Carson, F. Borgsten, S. Usmani

Get full text

PB2014: TECLISTAMAB VS SELINEXOR-DEXAMETHASONE IN PATIENTS WITH TRIPLE-CLASS EXPOSED RELAPSED/REFRACTORY MULTIPLE MYELOMA: A MATCHING-ADJUSTED INDIRECT COMPARISON by L. Rosinol, S. Z. Usmani, N. Bahlis, A. Y. Krishnan, A. K. Nooka, A. Oriol, M. Delforge, A. L. Garfall, N. W. van de Donk, P. Rodríguez Otero, T. G. Martin, J. Diels, S. Van Sanden, L. Pei, E. Ammann, R. Kobos, M. Slavcev, J. Smit, A. Londhe, P. Moreau

Get full text

Dreamm-4: evaluating safety and clinical activity of belantamab mafodotin (belamaf) in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (rrmm) by A. Medaglia, A.K. Nooka, M.V.M. Manteca, N. Bahlis, K. Weisel, A. Oriol, A.A. Alonso, A. Suvannasankha, B. Holkova, K. Luptakova, D. Fecteau, B.E. Kremer, M. Nichols, D. Williams, D.A Smith, R.C. Jewell, R. Montes de Oca, J. Opalinska, S. Trudel

Get full text

P922: HEALTH-RELATED QUALITY OF LIFE WITH TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FROM MAJESTEC-1 by R. Popat, P. Moreau, S. Z. Usmani, A. Garfall, M.-V. Mateos, J. F. San-Miguel, A. Oriol, A. K. Nooka, L. Rosinol, A. Chari, L. Karlin, A. Krishnan, N. Bahlis, T. Martin, B. Besemer, J. Martínez-López, M. Delforge, J. Fastenau, K. S. Gries, N. W. van de Donk

Get full text

B06: SUBCUTANEOUS TALQUETAMAB IN COMBINATION WITH DARATUMUMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): PHASE 1B RESULTS by M Mateos, P Hari, N Bahlis, A Chari, NWCJ van de Donk, B Dholaria, AL Garfall, H Goldschmidt, KM Kortüm, A Krishnan, T Martin, D Morillo, A Oriol, D Reece, C Rodriguez, P Rodríguez-Otero, JF San-Miguel, SZ Usmani, R Verona, SXW Lin, TJ Prior, M Wade, B Weiss, JD Goldberg, E Askari

Get full text

S183: NOVEL COMBINATION IMMUNOTHERAPY FOR THE TREATMENT OF RELAPSED/REFRACTORY MULTIPLE MYELOMA: UPDATED PHASE 1B RESULTS FOR TALQUETAMAB (A GPRC5D X CD3 BISPECIFIC ANTIBODY) IN CO... by N. W. van de Donk, N. Bahlis, M.-V. Mateos, K. Weisel, B. Dholaria, A. L. Garfall, H. Goldschmidt, T. G. Martin, D. Morillo, D. E. Reece, D. Hurd, P. Rodríguez-Otero, M. Bhutani, A. D’Souza, A. Oriol, E. Askari, J. F. San-Miguel, K. M. Kortüm, D. Vishwamitra, S. Xin Wang Lin, T. J. Prior, L. Vandenberk, M.-A. D. Smit, J. D. Goldberg, R. Wäsch, A. Chari

Get full text

P06: UPDATED RESULTS FROM THE PHASE 1/2 MAJESTEC-1 STUDY OF TECLISTAMAB, A B-CELL MATURATION ANTIGEN X CD3 BISPECIFIC ANTIBODY, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOM... by R Popat, S Usmani, A Garfall, N van de Donk, H Nahi, J San-Miguel, A Oriol, A Nooka, T Martin, L Rosinol, A Chari, L Karlin, L Benboubker, M Mateos, N Bahlis, P Moreau, B Besemer, J Martínez-López, S Sidana, L Pei, D Trancucci, R Verona, S Girgis, Y Olyslager, M Jaffe, C Uhlar, T Stephenson, R Van Rampelbergh, A Banerjee, J Goldberg, R Kobos, A Krishnan

Get full text